Akero Therapeutics, Inc. — Director's Dealing 2021

Apr 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Akero Therapeutics, Inc. (AKRO)
CIK: 0001744659
Period of Report: 2021-04-22

Reporting Person: Xu Yuan (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-22	Stock Option (Right to Buy)	$28.79	A	26000	Disposed	2031-04-22	Common Stock (26000)	Direct

Footnotes

F1: This option shall vest and become exercisable in 36 equal monthly installments, commencing on April 22, 2021.